Insight into the enzyme-inhibitor interactions of the first experimentally determined human aromatase

Area of Science:

• Biochemistry
• Pharmacology
• Computational Chemistry

Background:

• Intratumoral aromatase drives local estrogen production, making it a key target in hormone-sensitive breast cancer therapy.
• Aromatase inhibition is an effective strategy for treating breast cancer by suppressing estrogen biosynthesis.
• Recent determination of human placental aromatase cytochrome P450 structure provides insights into enzyme function and inhibitor binding.

Purpose of the Study:

• To elucidate the structural and functional characteristics of aromatase.
• To understand the precise binding modes of various aromatase inhibitors.
• To identify key amino acid residues involved in inhibitor interactions within the aromatase active site.

Main Methods:

• Molecular docking simulations were performed using twelve different inhibitors.
• Inhibitors included FDA-approved drugs, flavonoids, herbal compounds, and biphenyl-motif compounds.
• Interactions were analyzed within the active site of the human aromatase enzyme.

Main Results:

• All twelve tested ligands exhibited favorable interactions with the human aromatase active site.
• Key interactions were observed with hydrophobic residues (Ile133, Phe134, Phe221, Trp224, Ala306, Val370, Val373, Met374, Leu477) and hydrophilic/neutral residues (Arg115, Thr310).
• The study elucidated specific binding modes of inhibitors, contributing to structure-function relationship understanding.

Conclusions:

• The molecular docking study provides critical insights into the structure-function relationship of aromatase.
• Understanding the exact binding modes of inhibitors is vital for developing more effective anti-cancer drugs.
• These findings hold significant promise for advancing breast cancer therapy through targeted aromatase inhibition.